Original article

Geographic distribution of cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in Saudi Arabia

Hanaa Banjar a, *, Ibrahim Al-Mogarri a, Imran Nizami b, Sami Al-Haider a, Talal AlMaghmsi c, Sara Alkaf d, Abdulaziz Al-Enazi e, Nabil Moghrabi e

a Department of Pediatrics, King Faisal Specialist Hospital and Research Center (KFSHRC), Riyadh, Saudi Arabia
b Department of Biostatistics, Epidemiology and Scientific Computing, King Faisal Specialist Hospital and Research Center (KFSHRC), Riyadh, Saudi Arabia
c Department of Genetics, Molecular Diagnostic Laboratory, The Research Center, KFSHRC, Riyadh, Saudi Arabia
d Department of Pediatrics, King Faisal Specialist Hospital and Research Center (KFSHRC), Riyadh, Saudi Arabia
e Department of Biostatistics, Epidemiology and Scientific Computing, King Faisal Specialist Hospital and Research Center (KFSHRC), Riyadh, Saudi Arabia

Abstract

Introduction: Cystic fibrosis (CF) has been reported before in Saudi Arabia and the Gulf area. It has been found that screening for 10 most common cystic fibrosis transmembrane conductance regulator (CFTR) mutations can detect 80% of positive CFTR cases.

Objectives: To determine the geographic distribution of the most common CFTR variants in 5 regions of Saudi Arabia.

Methodology: A retrospective chart review of all CFTR variants conducted from January 1, 1992 to December 1, 2017.

Results: The ten most common CFTR mutations in the Saudi population were as follows: p.Gly473-GluFsX54 (17%), p.Phe508del (12%), p.Ile1234Val (12%), c.3120T>C (10%), p.Gln637Hisfs (5%), p.Ser549Arg (3%), p.Glu1521_1523delCTT (2%), c.2988+1G>T (2%), and c.3700A>G (2%) along with other variants 79 (20%). In terms of the highest frequency, the c.2988+1G>T (3120+1G>A) variant was found in the eastern province (7.3%) of Saudi Arabia, the c.1418delC (Cys473Ser) variant in the northern province (6.8%), the c.579+1G>T (711+1G>T) variant in the southern province (4.8%), the c.3700A>G (p.Ile1234Val) variant in the central province (4.8%), and c.1521_1523delCTT (p.Phe508del) variant in the western province (4.3%).

Conclusion: The eastern and the northern provinces have the highest prevalence of CF, with the c.2988+1G>T (3120+1G>A) and c.1418delC (p.Gly473GluFsX54) variants showing the highest distribution in the Saudi CF population, which may reflect the effect of consanguinity within the same tribe. Proper family screening and counseling should be emphasized.

© 2019 Publishing services provided by Elsevier B.V. on behalf of King Faisal Specialist Hospital & Research Centre (General Organization), Saudi Arabia. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Cystic fibrosis (CF) is a lethal inheritable disease that affects multiple organ systems of the body [1–5]. According to the Cystic Fibrosis Foundation annual report, approximately 60,000 to 70,000 people suffer from CF globally. The prevalence of CF in the Middle East was reported to be 1 in 2500–5000[4].

* Corresponding author.
E-mail address: hanaa@kfshrc.edu.sa (H. Banjar).
Peer review under responsibility of King Faisal Specialist Hospital & Research Centre (General Organization), Saudi Arabia.
commonest in North Africa and the Mediterranean countries [8].

Another study from Latin America showed that 89 CFTR mutations were reported out of 4354 CF chromosomes. The most common mutations were p.Phe508del (47%), p.Gly542Ter (5%), p.N1303K (1.6%), p.Trp1282Ter (1.1%), and p.R1162X (0.96%). The p.Phe508del variant was common in Argentina (59%), the p.G542X variant in Costa Rica (25%), the p.N1303K variant and the p.Arg1162Ter variant in Uruguay (3% and 4%, respectively), and the p.Trp1282Ter variant in Chile (3%) [9].

CFTR variants in the Saudi population have been first described in 1999 [4,10]. The most common mutations were p.Gly473-Glu5x54 (17%) (legacy name: 1548delG; Econ 10) [11], p.Ile1234Val (12%) (legacy name: 11234V; Econ 19) [12], p.Phe508del (13%) (legacy name: [delta] F508; Econ 10) [11–13], 3120+1G > A (12%) (legacy name: 3120+1G > A; Intrn 16) [14], and p.His139Leu (12%) (legacy name: H139L; Econ 4) [11]. Screening for the previously mentioned variants could identify 60% of CF variants in Arabs.

A previous study in Saudi Arabia described the geographic distribution of CFTR variants in 70 patients from 46 families during 1992–1997. The p.Gly473-Glu5x54 mutation (legacy name: 1548delG; Econ 10) (15%) was detected in the central province, the 3120+1G > A (legacy name: 3120+1G > A; Intrn 16) (10%) and p.His139Leu (legacy name: H139L; Econ 4) (7%) mutations were found mainly in the eastern province, and the p.Phe508del (legacy name: [delta]F508; Econ 10) (13%) was distributed equally in different provinces [10]. In this study, we report the updated geographic distribution of the most common CFTR variants in different geographic regions of Saudi Arabia with approximately 6 times the number of patients compared to that in the previous study from the same region in the last 20 years. Our center is considered the main referral center for patients with CF from all over the country.

1.1. Objectives

To determine the geographic distribution of the most common CFTR variants in 5 regions of Saudi Arabia.

2. Methodology

Retrospective data collection of all patients with CF referred to a CF clinic from 1992 to 2017. CF was diagnosed on a typical clinical picture of cough and sputum production, in addition to a history of CF in the immediate family and high sweat chloride test result >60 mmol/L in two subsequent samples by the Wescor quantitative method, USA [15], or pathologic CFTR mutations on both chromosomes.

2.1. CFTR identification

CFTR Gene Screen Methodology: DNA Isolation, PCR amplification of genomic DNA, mutational analysis, and sequencing methods have been described before in a previous study from the same center [16,17]. Variant detection was done by scoring using a publicly available variant database for CF such as “CF Mutation Database” (http://www.genet.sickkids.on.ca/CFTR/Home.html) or (http://www.hgmd.cf.ac.uk/ac/index.php). Both variant databases provided extensive repertoire of up-to-date sequence variants, deletions, and insertions for the CFTR gene.

2.2. Ethical considerations and statistical methods

Ethical approval was obtained from the research advisory committee. The Declaration of Helsinki and good clinical practice guidelines were followed. Data collection and data entry were supervised by the principal investigator. All data needed were obtained using a retrospective chart review and stored in pediatrics research unit, accessed only by the principal investigator and the assigned clinical research coordinator. The entire information of the patient was kept strictly confidential. Each patient was given a study number, and all patients’ data were entered into the designated data sheet (EXCEL) without any patient identification. The Department of Biostatistics Epidemiology and Scientific Computing (BESC) carried out statistical analysis of the data. The frequency of events was obtained from mean (SD), with simple descriptive analysis.

3. Results

A total of 396 patients with confirmed CF had positive CFTR variants from January 1, 1992 to December 1, 2017. Age at diagnosis was 3.4 (±SD 5 years), and age at follow-up was 10.2 (6.9) years. Consanguinity between parents was found to be in 85% of our population with CF.

Of the 396 patients with CF, 144 (37%) were referred from the eastern region of Saudi Arabia, 84 (21%) from the central region, 79 (20%) from the western region, 54 (13%) from the northern region, and 35 (9%) from the southern region (Table 1).

The most frequent CFTR variants in the Saudi population were c.1481delG (p.Gly473-Glu5x54) (17%) [11,18], c.1521_1523delCTT (p.Phe508del) (12%) [11–13], c.3700A > G (p.Ile1234Val) (12%) [12], c.2988 + 1G > A (p.Trp1282Ter) (11%) [13,14], c.416A > T (p.His139Leu) (6%) [11], c.579 + 1G > A (p.Cys581Tyr) (9%) [19], c.1911delC (p.Gln637Hisfs) (5%) [18], c.1647T > G (p.Ser549Arg) (3%) [20], c.3909C > G (p.Asn1303Lys) (3%) [21], and delEcon19-21 (2%) [22] along with other variants 79 (20%) (Table 1).

In terms of the highest frequency, the c.1481delG (p.Gly473-Glu5x54) variant was found in the northern province (6.8%), the c.1521_1523delCTT (p.Phe508del) variant was found in the western province (4.3%), the c.579 + 1G > A (p.Cys581Tyr) variant in the southern province (4.8%), the c.3700A > G (p.Ile1234Val) variant in the central province (4.8%), the c.2988 + 1G > A (p.Trp1282Ter) variant in the eastern province (7.3%), which also represents the highest variant in Saudi Arabia (Table 1).

The eastern province has the highest CF population of 145 patients (37%), which does not reflect the actual province’s population of 4,780,619 (15%) of the total Saudi population’s count in 2016 (Table 2) [23], i.e., it has double the frequency of patients with CF compared to that of other provinces, with a prevalence of 1:3000. Similarly, the northern province has a high CF prevalence of 1:2,000, whereas the other provinces have a low prevalence that ranges from 1:70,000 to 1:90,000 (Table 2) [23].

When comparing the present study with the earlier study from the same center in 1999, we found that despite the redistribution of population density according to the economic growth and the doubling of the population. Resting in the eastern, western, and central regions, the eastern provinces remaining with the highest CF prevalence of 1:3000 [24].

4. Discussion

It is well known that the most common CFTR variant in the Western world is p.Phe508del in approximately 66–75% of the CF population [25]. In contrast to the Saudi population, there is no single common variant but 10 different variants that constituted 80% of the total CFTR variants.

We have shown that the northern and eastern provinces have the highest CF prevalence of 1:2000 to 1:3,000, respectively (Table 2), whereas the other provinces have a low prevalence that
ranges from 1:70,000 to 1:90,000 (Table 2) [23]. We believe that lower access of care with regard to genetic counseling, preimplantation genetic diagnosis, and in vitro fertilization that are available in other provinces have contributed to the high prevalence of CF in the northern and eastern provinces. In contrast, the central and western provinces are cosmopolitan areas and highly attractive for business and investment, where a mixture of Arabic population were married to each other and may have diluted the prevalence of CF in this area (1:70,000 to 1:90,000) [23]. For these reasons, special attention should be paid for CFTR screening of such patients in our community, and proper family screening and counseling should be emphasized.

**Limitations**

Our CFTR screening reflected approximately 80% of patients with CF only in the KSA.

**Declaration of competing interest**

The authors declare no conflict of interest.

**CRediT authorship contribution statement**

Hanaa Banjar: Conceptualization, Methodology, Investigation, Supervision, Funding acquisition, Data curation, Formal analysis, Resources, Writing - original draft, Writing - review & editing. Ibrahim Al-Mogarri: Methodology, Supervision, Data curation, Writing - original draft, Writing - review & editing. Imran Nizami: Methodology, Supervision, Data curation, Writing - original draft, Writing - review & editing. Talal AlMaghamsi: Methodology, Supervision, Data curation, Writing - original draft, Writing - review & editing. Sara Alkaf: Investigation, Data curation, Formal analysis, editing.

### Table 1

Distribution of the 10 most common CFTR variants in the different geographic provinces of Saudi Arabia (total number of patients = 396).

| # | Ref # | Mutation | Nucleotide Change | Legacy name | refSNP | E (%) | W (%) | C (%) | N (%) | S (%) | Total (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 11,13 | p.Gly473ClnufX54 | c.1418delG | 1548delG; Exon 10 | rs397508205 | 12 (3.0) | 10 (2.5) | 16 (4.0) | 27 (6.8) | 3 (0.8) | 68 (17.2) |
| 2 | 1,13 | p.Phe508del | c.1521_1523delCTT | [delta]I508; Exon 10 | rs11393960 | 3 (0.8) | 17 (4.3) | 16 (4.0) | 7 (1.8) | 3 (0.8) | 46 (11.6) |
| 3 | 12 | p.Le1234Val | c.3700A>G | I1234V; Exon 19 | rs75389940 | 17 (4.3) | 6 (1.5) | 19 (4.8) | 3 (0.8) | 1 (0.3) | 46 (11.6) |
| 4 | 14 | 3120 + 1G>A | c.2988+1G>A | 3120 + 1G=A; Intron 16 | rs75986551 | 29 (7.3) | 7 (1.8) | 4 (1.0) | 1 (0.3) | 2 (0.5) | 43 (11.0) |
| 5 | 19 | 711 + 1G>T | c.579+1G>T | 711 + 1G>T; Intron 5 | rs77188391 | 3 (0.8) | 7 (1.8) | 5 (1.3) | 2 (0.5) | 19 (4.8) | 36 (9.0) |
| 6 | 11 | p.His139Leu | c.416A>G | H139L; Exon 4 | rs7637115 | 17 (4.3) | 4 (1.0) | 1 (0.3) | 3 (0.8) | 1 (0.3) | 26 (6.6) |
| 7 | 18 | p.Gln379Hisfs | c.1911delG | 2043delG; Exon 13 | rs1554389296 | 19 (4.8) | 1 (0.3) | - | - | - | 20 (5.0) |
| 8 | 20 | p.Ser549Arg | c.1647T>G | S549R; Exon 12 | rs121909005 | 11 (2.8) | 1 (0.3) | 1 (0.3) | 1 (0.3) | - | 14 (3.5) |
| 9 | 6 | p.N1303K | c.3909C>G | N1303K; Exon 21 | rs80004486 | 8 (2.0) | 1 (0.3) | 2 (0.5) | - | - | 11 (3.0) |
| 10 | 12 | delExon19-21 | - | - | - | 3 (0.8) | 1 (0.3) | 1 (0.3) | 3 (0.8) | 8 (2.0) | 20 (5.0) |
| Others | 26 | 6.6 | - | - | - | - | - | - | - | - | 79 (20) |
| Total | 145 | 37 | 79 | 20 | 35 | 9.0 | 396 | 100 |

**Legend**

- #: Number
- C=Central
- Ref=References
- N=North
- E=East
- S=South
- W=West
- refSNP= Reference Single Nucleotide Polymorphism Database, https://www.ncbi.nlm.nih.gov/snp/

### Table 2

Comparison of the Distribution of CF prevalence in relation to the population density of each geographic region between 2 studies.

| Region | Total KSA population | % of total population | # CF pts | % of CF pts | Prev | Total SA population | % of total population | # CF pts | % of CF pts | Prev |
|---|---|---|---|---|---|---|---|---|---|---|---|
| East | 2,542,258 | 15 | 19 | 27 | 1:10,000 | 4,780,619 | 15 | 145 | 37 | 1:3000 |
| Central | 4,355,735 | 25.7 | 23 | 33 | 1:70,000 | 9,390,095 | 29.6 | 84 | 21 | 1:9000 |
| West | 4,915,032 | 29 | 17 | 24 | 1:40,000 | 10,405,740 | 32.8 | 79 | 20 | 1:7000 |
| North | 1,525,354 | 9 | 3 | 4 | 1:20,000 | 2,432,285 | 7.7 | 53 | 13 | 1:2000 |
| South | 3,610,006 | 21.3 | 8 | 12 | 1:30,000 | 4,733,568 | 14.9 | 35 | 9 | 1:7000 |
| Total | 16,948,388 | 100 | 70 | 100 | 396 | 100 |

**Legend**

- #: Number.
- KSA=Kingdom of Saudi Arabia.
- Pts=patients.
- Prev=Prevalence.

### 5. Conclusion

The eastern and northern provinces have the highest prevalence of CF, which may reflect the effect of consangunility within the same tribe. Proper family screening and counseling should be emphasized.

For these reasons, special attention should be paid for CFTR screening of such patients in our community, and proper family counseling should be applied.

We believe that the high rates of familial intermarriages among carriers of these variants have perpetuated certain CFTR variants, especially the eastern and northern provinces. Consangunility between parents in our CF population was 85% compared to that of 50% overall in Saudi Arabia. We believe that CF has become a common disease in our population owing to the consangunility phenomenon despite being an orphan disease in other parts of the world.

**References**

1. Reference Single Nucleotide Polymorphism Database, https://www.ncbi.nlm.nih.gov/snp/

**Declaration of competing interest**

The authors declare no conflict of interest.
Acknowledgment

The authors acknowledge the following people:
(1) Maha Al-Eid, PhD, Biostatistics, Epidemiology, and Scientific Computing Department, KFSHRC, Riyadh.
(2) Manal Sheik, Department of Pediatrics Research Unit, KFSHRC.
(3) Dheaf AlAbdaly, Biostatistics, Epidemiology, and Scientific Computing Department, KFSHRC, Riyadh.
(4) Abdullah Almghabri, MD, Department of Pediatrics, KFSHRC.
(5) Abdulrhman AlOwaini, MD, Department of Pediatrics, KFSHRC.
(6) YOUSEF SEBEIH, MD, Department of Pediatrics, KFSHRC.
(7) Salman Al Muammar, College of Medicine, Al-Faisal University, Riyadh.
(8) Abdulaiz Al Sebiheen, Department of Pediatrics, KFSHRC.
(9) BIOpharma Middle East &amp; Africa, P.O. Box 214889, Dubai United Arab Emirates. Tel: +971 (4) 3692828; Fax: +971 (4) 3697391. www.biopharma-me.com.

References

1. Kambouris M, Banjar H, Moggari I, Nazer H, Al-Hamed M, Meyer BF. Identification of novel mutations in Arabs with cystic fibrosis and their impact on the cystic fibrosis transmembrane regulator mutation detection rate in Arab populations. Eur J Pediatr 2000;159(5):303–9. https://doi.org/10.1007/s004310051277.

2. Banjar H. Overview of Cystic Fibrosis: patients aged 1–12 years in a tertiary care center in Saudi Arabia. Middle East Pediatrics Dec 1999;4(2):44–9.

3. Banjar H. Morbidity and mortality data of cystic fibrosis patients. Saudi Med J 2003;24(7):730–5.

4. Banjar H, Angloalos G. The road for survival improvement of cystic fibrosis patients in Arab countries. Int J Pediatr. Adolesc. Med. 2015;2:47–58. https://doi.org/10.1016/j.ijpam.2015.05.006.

5. Cutting GR. Modifier genes in Mendelian disorders: the example of cystic fibrosis. Ann N Y Acad Sci 2010;1214:57–69. https://doi.org/10.1111/j.1749-6632.2010.05679.x.

6. Estivill X, Bancelis C, Ramos C. Geographic distribution and regional origin of 272 cystic fibrosis mutations in European populations. The Biomed CF Mutation Analysis Consortium. Hum Mutat 1997;10:135–54.

7. European cystic fibrosis society patient registry annual data report. https://www.ecfs.eu/projects/ecfs-patient-registry/annual-reports; 2017.

8. Mirjani S, et al. Geographical distribution of cystic fibrosis: the past 70 years of data analysis Biomed. Biotechnol. Res. J. 2017;1:105–12.

9. Pérez MM, Luna MC, Piveta OH, KeyeuGC. CFTR gene analysis in Latin American CF patients: heterogeneous origin and distribution of mutations across the continent. J Cyst Fibros 2007;6(3):194–208.

10. Banjar H, Kambouris M, Meyer BF, Al-Mehaideb A, Mogarrab I. Geographic distribution of cystic fibrosis transmembrane regulator gene mutations in Saudi Arabia. Ann Trop Paediatr 1999;19:69–73. https://doi.org/10.1080/0272499992671.

11. El-Harith EA, Dork T, Stuhmann M, Abu-Share H, Al-Shahri A, Keller KM, et al. Novel and characteristic CFTR mutations in Saudi Arab children with severe cystic fibrosis. J Med Genet 1997;34:996–9. https://doi.org/10.1136/jmg.34.12.996.

12. Claustrès M, Gerrard B, Kjellberg P, Desgeorges M, Demaille J, Dean M. Screening for cystic fibrosis mutations in Southern France: identification of a frameshift mutation and two missense variations. Hum Mutat 1992;1:310–3. https://doi.org/10.1002/humu.1380010408.

13. Riordan J. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Trends Genet 1989;5:363. https://doi.org/10.1016/0168-9525(90)90157-1.

14. Wilshanski M, Zielenki J, Markiewicz D, Tsiu L-C, Corey M, Levison H, et al. Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations. J Pediatr 1995;127:705–10. https://doi.org/10.1016/S0022-3476(95)70157-5.

15. LeCys VA. Sweat testing for the diagnosis of cystic fibrosis: practical considerations. J Pediatr 1996;129:892–7.

16. Bruns J. PCR: the basics of the polymerase chain reaction. MLO (Med Lab Obs) 2013;45(4):32–4.

17. Govaerts L, Adevem W, Esthee M, Mossey P, Busch T, Arebesosla B, et al. Association studies and direct DNA sequencing implicate genetic susceptibility Loci in the etiology of nonsyndromic orofacial clefts in sub-saharan African populations. J Dent Res 2016;95:1245–56. https://doi.org/10.1177/0022034516657003.

18. Fanen P, Ganhem N, Vidaud M, Besmond C, Martin J, Costes B, et al. Molecular characterization of cystic fibrosis: 16 Novel mutations identified by analysis of the whole cystic fibrosis conductance transmembrane regulator (CFTR) coding regions and splice site junctions. Genomics 1992;13:770–6. https://doi.org/10.1016/0888-7543(92)90152-i.

19. Zielenki J, Bozon D, Kerem B, Markiewicz D, Durie P, Rommens JM, et al. Identification of mutations in exons 1 through 8 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics 1991;10:229–35.

20. Kerem BS, Zielenki J, Markiewicz D, Bozon D, Gazit E, Yahav J, et al. Identification of mutations in regions corresponding to the two putative nucleotide (ATP)-binding folds of the cystic fibrosis gene. Proc Natl Acad Sci 1990;87:8447–51. https://doi.org/10.1073/pnas.87.21.8447.

21. Osborne L, Knight R, Santos G, Hodson M. A mutation in the second nucleotide binding fold of the cystic fibrosis gene. Am J Hum Genet 1991;48(3):608.

22. Feuillet-Fieux M, Ferrec M, Gigarel N, Thuillier L, Sermet I, Steffann J, et al. Novel CFTR mutations in black cystic fibrosis patients. Clin Genet 2004;65:284–7. https://doi.org/10.1111/j.1399-0004.2004.00230.x.

23. General Authority for statistics Kingdom of Saudi Arabia. Demographic survey of Saudi Arabia. https://www.stats.gov.sa/sites/default/files/ar-census31-prim-03.pdf; 2016.

24. General Authority for statistics Kingdom of Saudi Arabia. Distribution of population in KSA regions by sex and nationality (Saudi and non-Saudi nationals) according to preliminary results of the general population and housing census. https://www.stats.gov.sa/sites/default/files/en-Census-1413_z.pdf; 1992.

25. Saleeden D, Frossard P. The cradle of the deltaF508 mutation. J Ayub Med. Coll. 2007;20(4):157–60.